Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2676 - 2700 of 3948 in total
ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.
Investigational
PRTX-100 is a highly-purified form of Staphylococcal Protein A that binds directly to monocytes and a subset of B-cells that are involved in the development and progression of various autoimmune diseases. These binding interactions enable the compound to modulate the function of these cells and restore the balance of the...
Investigational
CUDC-101 has been used in trials studying the treatment of Cancer, Tumors, Liver Cancer, Breast Cancer, and Gastric Cancer, among others.
Investigational
CXL-1020 is under investigation in clinical trial NCT01092325 (Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure).
Investigational
Investigational
Investigational
ATSN-101 is a adeno-associated virus serotype 5 encoding human retinal guanylate cyclase 1 gene (AAV5-GUCY2D)
Investigational
TSHA-105 is an adeno-associated virus serotype 9 (AAV9) vector with an engineered transgene encoding the human SLC13A5 protein.
Investigational
WU-NK-101 is an allogeneic CD3-depleted, CD56-enriched activated natural killer-cell product
Investigational
AOC 1001 is an antibody oligonucleotide conjugate (AOC), comprised of a human transferrin receptor 1 (TfR1) targeting, effector function null, humanized IgG1 antibody (AV01mAb) conjugated to one small interfering RNA (siRNA).
Investigational
CYNK-101 is an allogeneic human placental hematopoietic stem cell-derived natural killer (NK) cell therapy product that is genetically modified to express a variant of CD16 (CD16VP).
Investigational
Investigational
Anti-SARS-COV-2 REGN-COV2 is a combination of novel antibodies designed by Regeneron for both the prevention and treatment of SARS-COV-2, the virus that causes COVID-19. This drug is a combination of the antibodies REGN10933 and REGN10987, derived from humanized VelocImmune® mice in addition to blood samples from patients who have recovered...
Investigational
Matched Description: … designed by Regeneron for both the prevention and treatment of SARS-COV-2, the virus that causes COVID-19 ... humanized VelocImmune® mice in addition to blood samples from patients who have recovered from COVID-19 ... COVID-19 patients (non-hospitalized), and uninfected individuals at high-risk of infection, including …
Matched Categories: … Experimental Unapproved Treatments for COVID-19
N4-Hydroxyctidine, or EIDD-1931, is a ribonucleoside analog which induces mutations in RNA virions.[A193008,A193011] N4-hydroxycytidine was first described in the literature in 1980 as a potent mutagen of bacteria and phage. It has shown antiviral activity against Venezuelan equine encephalitis virus, and the human coronavirus HCoV-NL63 in vitro. N4-hydroxycytodine has been...
Experimental
Matched Categories: … Experimental Unapproved Treatments for COVID-19
An indolizidine alkaloid from the plant Swainsona canescens that is a potent alpha-mannosidase inhibitor. Swainsonine also exhibits antimetastatic, antiproliferative, and immunomodulatory activity.
Experimental
Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery.
Investigational
Matched Mixtures name: … ORNISASIN 500 MG/500 MG FILM TABLET, 10 ADET ... ORCIPOL 500 MG/500 MG FILM TABLET, 10 ADET ... SIPROFORTE 500 MG/ 500 MG FILM TABLET , 10 ADET …
Matched Products: … ORNITOP 500 MG FILM TABLET, 10 ADET ... BITERAL 500 MG FILM KAPLI TABLET, 10 ADET ... ALBITROL 500 MG FİLM KAPLI TABLET, 10 ADET …
Experimental
Investigational
CNDO-109 are CNDO-109-activated allogeneic natural killer cells.
Investigational
Experimental
Matched Iupac: … -10-one ... (12R)-12-(aminomethyl)-4-methoxy-8-thia-11,14-diazatricyclo[7.5.0.0^{2,7}]tetradeca-1(9),2(7),3,5-tetraen …
Ensovibep is under investigation in clinical trial NCT04501978 (ACTIV-3: Therapeutics for Inpatients With COVID-19).
Investigational
Matched Description: … under investigation in clinical trial NCT04501978 (ACTIV-3: Therapeutics for Inpatients With COVID-19
CN-201 is a humanized anti-CD3/CD19 bispecific antibody.
Investigational
HH-009 is a recombinant human IgG4 monoclonal antibody against FGF19 being studied for the treatment of hepatocellular carcinoma.
Investigational
Experimental
Displaying drugs 2676 - 2700 of 3948 in total